Off-Label Use of Atypical Antipsychotics: An Update
Summary of Studies Included in the Comparative Effectiveness Review (1 of 2)
Studies of efficacy, effectiveness, benefits, and adverse effects of atypical antipsychotics as treatment for several off-label indications are reported in the clinical literature. There are no reports of studies of off-label use of the newer atypical antipsychotics asenapine, iloperidone, and paliperidone. The atypical antipsychotic clozapine was not included in the review; clozapine can only be prescribed in a system that provides weekly monitoring for bone marrow-suppression disorders as a condition of receiving the treatment.
Keywords: asenapine | atypical antipsychotics | clozapine | iloperidone | off-label | paliperidone | second generation | antipsychotics
- Maglione M, Ruelaz Maher A, Hu J, et al. Off-Label Use of Atypical Antipsychotics: An Update. Comparative Effectiveness Review No. 43 (Prepared by the Southern California RAND Evidence-based Practice Center under Contract No. HHSA 290-2007-10062-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11(12)-EHC087-EF. Available at www.effectivehealthcare.ahrq.gov/offlabelantipsych.cfm.
Your slide tray is being processed.